Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Florian Krammer Profile picture
@florian_krammer
Jun 6, 2020 • 4 tweets • 1 min read • Read on X
1) Nipah virus is another virus to keep an eye on. It doesn't transmit between people well but it can to a certain degree, it has a high CFR and there are regular outbreaks. One vaccines is in clinical trials (funded by CEPI).
2) CEPI is funding clinical trials for vaccines against emerging viruses including Lassa, Nipah Marburg, MERS, Chikungunya, CCHF etc. CEPI is financed by Norway, Japan, Germany, the Gates Foundation and the Wellcome Trust. India is planning to contribute.
3) These CEPI-funded vaccines will potentially avoid future pandemics. The US is not contributing. Maybe tell you representatives that it would be a good idea to change that. cepi.net
4) I forgot some countries: Australia, Belgium, Denmark, the UK, Canada, Mexico and Ethiopia as well as the European Commission are contributing as well.

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Florian Krammer

Florian Krammer Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @florian_krammer

Florian Krammer Profile picture
Feb 25
1) I am reviewing some of the literature re antigenic distances between XBB.1.5 nd JN.1 and how well the XBB.1.5 vaccine works right now. I'll post random papers here. Just for nerds. (this is not a story, just a bunch of papers).
2) Interesting paper from Qatar re protection of infection from JN.1 reinfection. Take home message is probably that JN.1 is antigenically distant from XBB.1.5. medrxiv.org/content/10.110…
Image
3) Nice paper from the Netherlands (@dirkeggink) looking at XBB.1.5 vaccine effectiveness against XBB.1.5 and JN.1. Take home message: Vaccine works.
medrxiv.org/content/10.110…
Image
Read 18 tweets
Florian Krammer Profile picture
Aug 28, 2023
1) Our preprint describing 3 years of our PARIS study is live. There are a few interesting observations I wanted to highlight. This was the work of a large team but the lead is really @VivianaSimonLab medrxiv.org/content/10.110…
2) First, here is an overview of the spike titers of all the study time points. We had 501 individuals in the study and measure their anti-spike binding antibodies on a regular basis. Image
3) The first take home message is: Antibody decay after mRNA vaccination is biphasic. First a steep drop, then a stabilization phase. The graph here shows titers after the primary immunization series. Blue is previously naive individuals, orange is hybrid immune. Image
Read 17 tweets
Florian Krammer Profile picture
Aug 12, 2023
1) I feel this paper by Mattias Forsell's group is often overlooked but shows something very important: Binding antibody to SARS-CoV-2 spike - in the absence of strong neutralizing antibodies to a new variant - predict protection from mortality. .thelancet.com/journals/lanep…
2) Individuals with the lowest antibody titer have the highest risk, individuals with higher titers are protected. Of course, we are not talking about protection from infection or protection from symptomatic disease by binding, non-neutralizing antibodies here, but protection.... Image
3) ...from severe outcomes. Why is this important? Neutralizing antibodies (which likely are the main protective factor when it comes to protection from infection or symptomatic disease) often drop steeply against new variants while binding antibodies are in most cases.....
Read 7 tweets
Florian Krammer Profile picture
Aug 7, 2023
1) In a recent study with @gabagagan, Anass Abbad, Juan Manuel Carreño and @VivianaSimonLab we wanted to see how much crossreactivity exists in the post-COVID era to spikes beyond SARS-CoV-2. We expressed all the spikes shown in the tree below and got going. Image
2) We ran ELISAs with longitudinal samples from people who had received the primary vaccination series of COVID-19 mRNA vaccines including naive individuals (grey) and people who previously had SARS-CoV-2 infections (black). Image
3) Titers actually went up for all sarbecoviruses and even for most other betacoronaviruses (with the exception of nobecoviruses where there was no increase in reactivity for one of the two spikes tested).
Read 10 tweets
Florian Krammer Profile picture
Mar 17, 2023
1) I just talked with students in class about similar situations in France and Spain in the last few years. Aedes mosquitos are present in the US and Europe and are a nice vector for dengue. Once the virus is established in local mosquito populations its hard to get rid off.
2) And climate change helps the mosquitos to move north, extending the potential range for viruses like dengue, chikungunya, Zika etc. This is also happening for some tick species, e.g. Hyalomma ticks in Europe which can carry Crimean-Congo Hemorrhagic Fever Virus.
3) Some links here: ncbi.nlm.nih.gov/pmc/articles/P…
Read 5 tweets
Florian Krammer Profile picture
Feb 9, 2023
1) What should be done about avian influenza. Very easy. Master seed viruses and vaccines specific to the panzootic H5N1 need to be produced (which is likely in progress for a some time already, the CDC is really good at this and BARDA has manufacturing contracts for it).
2) It needs to be assess if these viruses are sensitive to the three classes of drugs we have against influenza. To my knowledge that has been done, looking good. There is likely also significant immunity to the N1 because humans have been exposed to pH1N1 which...
3) ...is now the seasonal H1N1 strain and features and avian origin N1 (see 1968 H2N2/H3N2 cross-protection for literature). Then, physicians need to be informed about the possibility that an atypical influenza they detect is H5N1. They need to review the tests they are running..
Read 7 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

Send Email!

:(